Congenital anomalies in newborns of women with type 1 diabetes: nationwide population‐based study in Norway, 1999–2004

Eidem, Ingvild; Stene, Lars C.; Henriksen, Tore; Hanssen, Kristian F.; Vangen, Siri; Vollset, Stein Emil; Joner, Geir

doi:10.3109/00016349.2010.518594

Cited by 69 publications

(50 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both animal and human studies have shown uncontrolled or poorly controlled maternal pregestational diabetes significantly increases the risk of offspring with major malformations [6,7]. Epidemiologic studies also have found a strong link between pregestational diabetes and birth defects [8,9].…”

Section: What Do We Know?mentioning

confidence: 98%

Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

Reece

2011

Curr Diab Rep

View full text Add to dashboard Cite

Birth defects are the leading cause of infant mortality in the United States, which has one of the highest infant mortality rates in the developed world. Many of these birth defects can be attributed to pre-existing, or pregestational, diabetes in pregnancy, which significantly increases a mother's risk of having a child with a major birth defect. Strict preconceptional and early pregnancy glucose control, supplementation with multivitamins and fatty acids, and lower glycemic dietary management have been shown to reduce the incidence of birth defects in experimental and epidemiologic studies. However, because more than half of pregnancies are unplanned, these methods are not generalizable across the population. Thus, better interventions are urgently needed. Based on what we know about the molecular pathophysiology of diabetic embryopathy, our laboratory and others are developing interventions against to key molecular targets in this multifactorial disease process.

show abstract

Section: What Do We Know?mentioning

confidence: 98%

Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

Reece

2011

Curr Diab Rep

View full text Add to dashboard Cite

show abstract

“…Diabetes inhibits mRNA and protein expression of both small (SK3) and intermediate (IK) conductance calcium-activated potassium channels in the cavernous tissue of diabetic rats, which could play a key role in the development of erectile dysfunction in diabetic rats (Zhu et al 2010). There are several reports in the literature that babies born to type I diabetic mothers are having altered growth and body composition, skeletal deformities as well as other abnormalities (Mughal et al 2010;Eidem et al 2010). Generation of oxidative stress in the hyperglycemic condition can result in reproductive dysfunction in experimental diabetic models (Agarwal and Said 2005).…”

Section: Introductionmentioning

confidence: 96%

Enalapril reduces germ cell toxicity in streptozotocin-induced diabetic rat: investigation on possible mechanisms

Kushwaha

Jena

2011

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Diabetes mellitus, a state of persistent hyperglycemia, is a major cause of micro- and macrovascular diseases. It affects nearly every system in the body including the reproductive system. Abnormalities in spermatogenesis and sexual function have been documented in animal models for both types of diabetes. The purpose of the present study is to determine the possible protective effects of enalapril against the germ cell toxicity in diabetic rat. Sprague-Dawley rats were divided into four groups: (1) control, (2) control + enalapril, (3) diabetic, and (4) diabetic + enalapril. Enalapril was administered per orally for 4 and 8 weeks continuously. After the treatment, animals were sacrificed and blood glucose level, sperm count, sperm DNA damage, apoptotic cell death, immunohistochemistry of 8-oxo- 7,8-dihydro- 2'-deoxyguanosine, and the cellular toxicity were performed. Furthermore, western blotting was performed to evaluate the expression of NFκB and COX-2 in testes. The results of the present study indicate that intervention of enalapril ameliorates the sperm DNA damage, reduces the oxidative stress, and down-regulates the expression of NFκB and COX-2 expression in streptozotocin-induced diabetic rat.

show abstract

“…Despite substantial advances in the treatment of type 1 diabetes over recent decades and focus on the necessity of good care before and during pregnancy for women with the disease, most research studies indicate that women with pregestational type 1 diabetes still have a considerably higher risk of pregnancy complications and adverse pregnancy outcome compared with the background population [1][2][3][4][5][6]. The risk of stillbirth or perinatal death has, according to recent studies, varied between three and six times the risk in women without diabetes [7].…”

Section: Introductionmentioning

confidence: 99%

Perinatal and infant mortality in term and preterm births among women with type 1 diabetes

et al. 2011

View full text Add to dashboard Cite

Aims/hypothesis The aim of this study was to estimate the risks of adverse birth outcomes such as stillbirth, infant death, preterm birth and pre-eclampsia in women with type 1 diabetes, compared with the background population. We further aimed to explore the risks of adverse birth outcomes in preterm and term deliveries separately. Methods By linkage of two nationwide registries, the Medical Birth Registry of Norway and the Norwegian Childhood Diabetes Registry, we identified 1,307 births among women with pregestational type 1 diabetes registered in the Diabetes Registry, and 1,161,092 births in the background population during the period 1985-2004. The ORs with 95% CIs for adverse outcome among women with type 1 diabetes vs the background population were estimated using logistic regression. Results The OR for stillbirth (≥22 weeks of gestation) was 3.6 (95% CI 2.5, 5.3), and for perinatal death (stillbirth or death in the first week of life) it was 2.9 (95% CI 2.0, 4.1). The OR for infant death (first year of life) was 1.9 (95% CI 1.1, 3.2). For preterm birth (< 37 weeks of gestation) and pre-eclampsia the ORs were 4.9 (95% CI 4.3, 5.5) and 6.3Electronic supplementary material The online version of this article (doi:10.1007/s00125-011-2281-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

show abstract

Congenital anomalies in newborns of women with type 1 diabetes: nationwide population‐based study in Norway, 1999–2004

Abstract: Women in Norway with type 1 diabetes experience a significantly higher risk of congenital anomalies in their babies compared with the background population.

Cited by 69 publications

References 25 publications

Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

Enalapril reduces germ cell toxicity in streptozotocin-induced diabetic rat: investigation on possible mechanisms

Perinatal and infant mortality in term and preterm births among women with type 1 diabetes

Contact Info

Product

Resources

About